1)Spaide RF, Fisher YL:Intravitreal bevacizumab(Avastin)treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278, 2006
2)Wakabayashi T, Oshima Y, Sakaguchi H et al:Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571-1580, 2008
3)Gheith ME, Siam GA, de Barros DS et al:Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 23:487-491, 2007
4)Kubota T, Aoki R, Harada Y et al:Intravitreal injection of bevacizumab to treat neovascular glaucoma. Jpn J Ophthalmology 52:410-412, 2008
5)伊藤由美子・川村亮介・鈴木浩太郎・他:Bevacizumab硝子体内投与が有効であった血管新生緑内障の一例.眼臨紀 2:303-305,2009
6)河田哲宏・山本直子・松下恭子・他:血管新生緑内障に対するベバシズマブ併用線維柱帯切除術の術後成績.臨眼 63:1457-1460,2009
7)Miki A, Oshima Y, Otori Y et al:Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol 92:1431-1433, 2008
8)Aiello LP, Avery RL, Arrigg PG et al:Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
9)Funatsu H, Yamashita H, Noma H et al:Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133:70-77, 2002
10)Wu L, Martínez-Castellanos MA, Quiroz-Mercado H et al;Pan American Collaborative Retina Group(PACORES):Twelve-month safety of intravitreal injections of bevacizumab(Avastin):results of the Pan-American Collaborative Retina Study Group(PACORES). Graefes Arch Clin Exp Ophthalmol 246:81-87, 2008
11)Fung AE, Rosenfeld PJ, Reichel E:The International Intravitreal Bevacizumab Safety Survey:using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349, 2006